The FDA panel vote did not approve anything.
In July 2026 an advisory committee voted to recommend six peptides for a compounding list. That is being reported as clearance. It is not.
Seven substances, one advisory vote
The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider whether seven peptides should be recommended for the 503A bulk drug substances list. FDA’s own review staff recommended against all seven, citing missing human clinical data and unresolved characterisation and quality questions. The committee voted the other way on six of them.
| Substance | FDA staff review | Committee vote |
|---|---|---|
| BPC-157 | Against | In favour |
| TB-500 | Against | In favour |
| KPV | Against | In favour |
| MOTS-c | Against | In favour |
| Epitalon | Against | In favour |
| Semax | Against | In favour |
| Emideltide | Against | Against |
Three things the vote did not do
- It did not add anything to a list
- The committee advises; it does not decide. Before a substance reaches the 503A list, FDA has to run a formal notice-and-comment rulemaking, which is expected to take more than a year. None of these substances is on the list today.
- It did not approve a drug
- The 503A list governs what a compounding pharmacy may compound from. It is not a marketing approval, and it says nothing about whether a compound is safe or effective.
- It did not create permission to sell
- Treating the vote as a green light to compound or market these substances carries enforcement risk until FDA formally acts. That risk sits with whoever acts on the misreading.
Nothing changes here
Two of the six peptides the committee voted for — BPC-157 and TB-500 — are compounds we supply. We are not going to present that as a tailwind, because the vote does not reach us.
- We are not a pharmacy
- Lyotide Scientific is a laboratory chemical supplier. It is not a compounding pharmacy under Section 503A and not an outsourcing facility under Section 503B. A bulks list for compounders is not a rule about us.
- Our terms are unchanged
- Research use only, sold to businesses, shipped unlabeled by the box. That was true before the vote and is true after it.
- We make no approval claim
- No compound in this catalog is approved by FDA for use in a person or an animal, including the six the committee voted for.
- If you are a compounder
- Take the timing and the enforcement question to your own regulatory counsel. We are not in a position to advise you and will not pretend otherwise.
Related reading: important safety notice and contaminant warnings.
Reported by Drug Topics and others following the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026. Read the report. This page is a summary of public regulatory news, not legal advice.